Stock Evaluator: Nanobiotix S.A. (NBTX)

Nanobiotix S.A. NBTX

$27.32 0.42 1.54%
November 19, 2026 4:00:00 PM EST November 10, 2021 Volume: 178,002
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Commentary & Analysis


Financial Summary

Share Statistics NBTX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,341.7 $213.9 50%
Shares Out (Mil) 55.8 55.4 50%
Institutional Ownership 81.9% 93.3% 50%
Float (Mil) 35.2 40.6 39%
Beta 0.59 0.98 33%
Avg Daily Volume (000s) 151 597 41%
Price Change
(52-week)
22.9% 40.9% 71%
Growth NBTX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 68.7% 13.2% 97%
Net Income (5yr) 7.3% (10.7%) 51%
EPS (5yr) 19.0% 15.5% 67
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (55.5%) (15.7%) 5%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials NBTX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $13 $39 10%
Net Income (TTM) (Mil) ($60) ($44) 14%
EPS (TTM) ($1.244) ($1.400) 18%
Operating Cash Flow (TTM) (Mil) ($39) ($34) 11%
Net Cash Flow (TTM) (Mil) $95 $-0 77%
Long-Term Debt (Q1) (Mil) $85 $4 43%
Enterprise Value (Q1) (Mil) $1,226 $135 44%
Valuation NBTX Industry
Median
Percentile
(All Stocks)
P/B na 1.97 na
P/E na 17.6 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.8 na
Ratios NBTX Industry
Median
Percentile
(All Stocks)
Gross Margin 100.0% 67.9% 96%
Net Margin (459.5%) (50.8%) 2%
ROA (60.5%) (47.5%) 9%
ROE 101.4% (51.9%) 96%
Liabilities to Assets 126.0% 29.7% 97%
F-Score 4 3 33%

Nanobiotix S.A. did not pass any screens on 11/18/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors